Katacine is a new ligand of CLEC-2 that acts as a platelet agonist
Background: CLEC-2 is a platelet receptor with an important role in thrombo-inflammation but a minor role in haemostasis. Two endogenous ligands of CLEC-2 have been identified, the transmembrane protein podoplanin, and iron-containing porphyrin hemin, which is formed following haemolysis from red blood cells. Other exogenous ligands such as rhodocytin have contributed to our understanding of the role of CLEC-2. Objectives: To identify novel CLEC-2 small molecule ligands to aid therapeutic targeting of CLEC-2. Methods: ALPHA Screen technology has been used for development of a high throughput screening (HTS) assay recapitulating the podoplanin-CLEC-2 interaction. Light transmission aggregometry was used to evaluate platelet aggregation. Immunoprecipitation and western blot were used to evaluate direct phosphorylation of CLEC-2 and downstream protein phosphorylation. Autodock vina software was used to predict the molecular binding site of katacine and mass spectrometry to determine the polymeric nature of the ligand. Results and conclusions: We developed a CLEC-2-podoplanin interaction assay in a HTS format and screened 5016 compounds from an EU-Open screen library. We identified katacine, a mixture of polymers of proanthocyanidins, as a novel ligand for CLEC-2 and showed that it induces platelet aggregation and CLEC-2 phosphorylation via Syk- and Src kinases. Platelet aggregation induced by katacine is inhibited by the anti-CLEC-2 monoclonal antibody fragment AYP1 F (ab)’2. Katacine is a novel non-protein ligand of CLEC-2 that could contribute to a better understanding of CLEC-2 activation in human platelets.
- Alternative title
-
Katacine: a new CLEC-2 platelet agonist
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Katacine is a new ligand of CLEC-2 that acts as a platelet agonist ; day:15 ; month:02 ; year:2022
Thrombosis and haemostasis ; (15.02.2022)
- Contributor
-
Morán, Luis A.
Di, Ying
Sowa, Marcin A.
Hermida-Nogueira, Lidia
Barrachina, María N.
Martin, Eleyna
Mize, Todd H.
Clark, Joanne C.
Eble, Johannes A.
Moreira, David
Pollitt, Alice Y.
Loza, María I.
Domínguez, Eduardo
Watson, Steve P.
Garcia, Angel
- DOI
-
10.1055/a-1772-1069
- URN
-
urn:nbn:de:101:1-2022040510075654359521
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Morán, Luis A.
- Di, Ying
- Sowa, Marcin A.
- Hermida-Nogueira, Lidia
- Barrachina, María N.
- Martin, Eleyna
- Mize, Todd H.
- Clark, Joanne C.
- Eble, Johannes A.
- Moreira, David
- Pollitt, Alice Y.
- Loza, María I.
- Domínguez, Eduardo
- Watson, Steve P.
- Garcia, Angel
Other Objects (12)
Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting
Unraveling Mechanisms that Control Platelet Production
Agonist-Evoked Increases in Intra-Platelet Zinc Couple to Functional Responses
Hypoxia impairs agonist-induced integrin αIIbβ3 activation and platelet aggregation
Prostaglandin E2 acts via the EP4 receptor to inhibit platelet aggregation
Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy
Exogenous human α-Synuclein acts in vitro as a mild platelet antiaggregant inhibiting α-thrombin-induced platelet activation
Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1
Characterization of human platelet binding of recombinant T cell receptor ligand
Artocarpesin acts on human platelet aggregation through inhibition of cyclic nucleotides and MAPKs
Kernel learning for ligand-based virtual screening: discovery of a new PPARγ agonist
Kernel learning for ligand-based virtual screening: discovery of a new PPARgamma agonist
Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting
Unraveling Mechanisms that Control Platelet Production
Agonist-Evoked Increases in Intra-Platelet Zinc Couple to Functional Responses
Hypoxia impairs agonist-induced integrin αIIbβ3 activation and platelet aggregation
Prostaglandin E2 acts via the EP4 receptor to inhibit platelet aggregation
Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy
Exogenous human α-Synuclein acts in vitro as a mild platelet antiaggregant inhibiting α-thrombin-induced platelet activation
Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1
Characterization of human platelet binding of recombinant T cell receptor ligand
Artocarpesin acts on human platelet aggregation through inhibition of cyclic nucleotides and MAPKs
Kernel learning for ligand-based virtual screening: discovery of a new PPARγ agonist
Kernel learning for ligand-based virtual screening: discovery of a new PPARgamma agonist
Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting
Unraveling Mechanisms that Control Platelet Production
Agonist-Evoked Increases in Intra-Platelet Zinc Couple to Functional Responses
Hypoxia impairs agonist-induced integrin αIIbβ3 activation and platelet aggregation
Prostaglandin E2 acts via the EP4 receptor to inhibit platelet aggregation
Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy
Exogenous human α-Synuclein acts in vitro as a mild platelet antiaggregant inhibiting α-thrombin-induced platelet activation
Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1
Characterization of human platelet binding of recombinant T cell receptor ligand
Artocarpesin acts on human platelet aggregation through inhibition of cyclic nucleotides and MAPKs
Kernel learning for ligand-based virtual screening: discovery of a new PPARγ agonist